As Pfizer's new chief of vaccine research and development, Annaliesa Anderson has a high bar to reach as she replaces retiring Kathrin Jansen, who climaxed her career with a brilliant swan song—leading Pfizer’s collaboration with BioNTech which produced the world’s most successful COVID-19 vaccine.
Michael Severino, M.D., is leaving AbbVie and big pharma behind—but that’s not the end of the story. The leader is already entering his next chapter at Tessera Therapeutics, stepping into the world of biotech as CEO of the gene writing and rewriting company.
Wednesday afternoon's "deliberate" attack sent the 1,112-bed hospital's entire campus into lockdown and led to the deaths of four victims. It is the latest in a string of mass shootings across the country.
In news that’ll certainly be music to many ears, a surgeon-led team in Texas was able to successfully implant what it says is the first ear to be 3D-printed using the patient’s own cells.
It’s the rare triple down: Bristol Myers Squibb is once again revising a massive research collaboration with immunotherapy drug discovery biotech Immatics. BMS is adding a new deal with $60 million upfront and $700 million down the line for at least two new programs, plus expanding its prior arrangement.
Regeneron has acquired worldwide rights to cancer drug Libtayo from Sanofi for $900 million. Sanofi also will receive an 11% royalty on global sales of Libtayo as well as $100 million in regulatory milestone payments and up to $100 million in sales-related milestone payments over the next two years.
The last time Samantha Truex was CEO of a biotech, she did something rare: She admitted defeat. Now, Truex is back at the helm of Upstream Bio, a new inflammatory disease biotech that has been quietly building over the past few months and is ready to reveal today with a whopping $200 million in financing.
Software maker Oracle cleared the final regulatory hurdle for its pending $28.3 billion acquisition of Cerner, the companies announced Wednesday. The deal is set to close next week.
Diabeloop's hybrid closed-loop insulin delivery system may soon make its way stateside, thanks to an infusion of venture capital that the French company announced this week.
As the protein degradation field continues to grow, Merck KGaA has decided it needs more than one baton in the metaphorical clinical relay race, inking a $554 million deal with Austrian biotech Proxygen.
One expert says physicians should be ready to help identify potential cases of monkeypox and know what to look for as spread of the virus continues across the globe.
